Evidence map›Paper›PMID 42707719›Full record

ArticleTheranostics2026

Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.

Amanda Gustafsson, Anja Charlotte Lundgren Mortensen, Veronica Rondahl, Tianqi Xu, Klas Bratteby, Peter Bernhardt, Marika Nestor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amanda GustafssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, 752 37, Uppsala, Sweden.
Anja Charlotte Lundgren MortensenDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, 752 37, Uppsala, Sweden.
Veronica RondahlDepartment of Animal Biosciences, Swedish University of Agricultural Sciences, 750 07, Uppsala, Sweden.
Tianqi XuDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, 752 37, Uppsala, Sweden.
Klas BrattebyDepartment of Nuclear Medicine and Medical Physics, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Peter BernhardtDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Marika NestorDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, 752 37, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Lutetium-177 has demonstrated clinical success, particularly in neuroendocrine and prostate cancers, but disease recurrence and progression remain frequent. Terbium-161 offers improved therapeutic potential by delivering higher localized radiation doses. We have previously demonstrated preclinical efficacy of the CD44v6-targeted radiopharmaceutical [ Methods: Radioligand uptake was evaluated Results: Specific, high-affinity binding of [ Conclusion: [

Indexed as

Carcinoma, Pancreatic DuctalCarcinoma, Squamous CellHyaluronan ReceptorsPancreatic NeoplasmsRadioisotopesRadiopharmaceuticalsTerbiumAnimalsCell Line, TumorFemaleHumansLutetiumMaleMiceRadiometryTissue DistributionCD44v6 antigenHyaluronan ReceptorsLutetiumRadioisotopesRadiopharmaceuticalsTerbiumCD44v6pancreatic ductal adenocarcinomasquamous cell carcinomatargeted radionuclide therapyterbium-161

Identifiers

PMID42707719
PMCPMC13549377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.